Print  Close

Evaluating quantification methods for tau PET in progressive supranuclear palsy

Poster No:

1627 

Submission Type:

Abstract Submission 

Authors:

Roxane Dilcher1, Callum Taylor2, Cassandra Marotta2, Charles Malpas3, Terence O’Brien4, Lucy Vivash4

Institutions:

1Monash University, Brunswick, VIC, 2Monash University, Melbourne, Australia, 3Melbourne University, Melbourne, Australia, 4Monash University, Melbourne, VIC

First Author:

Roxane Dilcher  
Monash University
Brunswick, VIC

Co-Author(s):

Callum Taylor  
Monash University
Melbourne, Australia
Cassandra Marotta  
Monash University
Melbourne, Australia
Charles Malpas  
Melbourne University
Melbourne, Australia
Terence O’Brien  
Monash University
Melbourne, VIC
Lucy Vivash  
Monash University
Melbourne, VIC

Introduction:

Quantifying the standardized uptake value ratio (SUVr) in [18F]PI-2620 tau-PET for tauopathies remains challenging. This study evaluated the impact of different reference regions and partial volume correction (PVC) on longitudinal tau-PET changes in progressive supranuclear palsy (PSP) to assess disease progression.

Methods:

Subcortical [18F]PI-2620 tau-PET SUVr was analysed in 24 patients with clinically diagnosed probable PSP (Richardson's syndrome) at baseline and week 52, comparing reference regions with and without PVC. Associations with changes in total MRI brain volume, cerebrospinal fluid and blood biomarkers, and disease severity were examined.

Results:

Without PVC, higher tau signals were observed with the whole cerebellum, cerebellar grey matter, parametric estimation of reference signal intensity (PERSI), and pons reference regions compared to white matter (baseline: M=1.32; SD=0.14; 95% CI, -0.05--0.10). After PVC, white matter showed the highest tau signal (baseline: M=1.63; SD=0.95; 95% CI, -0.5-0.12). Strong associations with brain volume decline (β = -3.8; 95% CI, -6.1--1.5 p = .003), plasma GFAP/NfL ratio decrease (β=-0.04; 95% CI, -0.07-0.02 p=.001), and cerebrospinal fluid t-tau (β=-0.04; 95% CI, -0.07-0.02 p=.001) and NfL (β=0.000; 95% CI, 0.000--0.001, p=.005) increase were found using cerebellar grey matter or pons without PVC, and pons with PVC showed stronger associations with disease severity (β=0.17; 95% CI, 0.090-0.25, p<.001). Baseline biomarker levels predicted tau changes more effectively with pons or PERSI references without PVC, but less so after PVC.
Supporting Image: abstract.png
   ·Pallidum SUVr dynamics across reference regions
 

Conclusions:

Subcortical SUVr changes depend on reference region selection and PVC application, highlighting the importance of accurate quantification methods for tau-PET in clinical trials and diagnostic workflows.

Disorders of the Nervous System:

Neurodegenerative/ Late Life (eg. Parkinson’s, Alzheimer’s) 2

Modeling and Analysis Methods:

PET Modeling and Analysis 1

Novel Imaging Acquisition Methods:

PET

Keywords:

Blood
Cerebro Spinal Fluid (CSF)
Movement Disorder
MRI
Positron Emission Tomography (PET)

1|2Indicates the priority used for review

Abstract Information

By submitting your proposal, you grant permission for the Organization for Human Brain Mapping (OHBM) to distribute your work in any format, including video, audio print and electronic text through OHBM OnDemand, social media channels, the OHBM website, or other electronic publications and media.

I accept

The Open Science Special Interest Group (OSSIG) is introducing a reproducibility challenge for OHBM 2025. This new initiative aims to enhance the reproducibility of scientific results and foster collaborations between labs. Teams will consist of a “source” party and a “reproducing” party, and will be evaluated on the success of their replication, the openness of the source work, and additional deliverables. Click here for more information. Propose your OHBM abstract(s) as source work for future OHBM meetings by selecting one of the following options:

I do not want to participate in the reproducibility challenge.

Please indicate below if your study was a "resting state" or "task-activation” study.

Other

Healthy subjects only or patients (note that patient studies may also involve healthy subjects):

Patients

Was this research conducted in the United States?

No

Were any human subjects research approved by the relevant Institutional Review Board or ethics panel? NOTE: Any human subjects studies without IRB approval will be automatically rejected.

Yes

Were any animal research approved by the relevant IACUC or other animal research panel? NOTE: Any animal studies without IACUC approval will be automatically rejected.

Not applicable

Please indicate which methods were used in your research:

PET

Which processing packages did you use for your study?

SPM
FSL

Provide references using APA citation style.

not applicable

UNESCO Institute of Statistics and World Bank Waiver Form

I attest that I currently live, work, or study in a country on the UNESCO Institute of Statistics and World Bank List of Low and Middle Income Countries list provided.

No